CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Cristal Therapeutics develops advanced nanoparticles to deliver cancer drugs more effectively. Their CriPec® technology aims to enhance treatment for ovarian and bladder cancer by personalizing therapy based on tumor targeting, improving safety and efficacy for patients.
Cristal Therapeutics (CT) develops the next generation of nanomedicines to treat cancer.
Cancer remains one the leading causes of death worldwide, and current treatment options are insufficient, in part due to the tumour heterogeneity between patients. CT has developed state-of-the-art nanoparticles (CriPec®) to target a drug of choice more selectively to the tumour site(s).
The superior therapeutic performance of this approach has already been demonstrated preclinically for CT’ lead product Cri…
CRISTAL DELIVERY BV
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
